WuXi AppTec took part in a round that Canbridge Life Sciences will put toward clinical trials of two cancer immunotherapies for use in its home country of China.
China-based biopharmaceutical company Canbridge Life Sciences has closed a $25m series B round featuring WuXi AppTec, the pharmaceutical research and development company also known as WuXi PharmaTech.
Life sciences-focused venture capital firm Lapam Capital led the round, with participation from Qiming Venture Partners, Yuanming Capital, Yanyuan Capital and Biossom Investment Management.
Founded in 2012, Canbridge partners western pharmaceutical companies to bring clinical-stage drugs, medical devices or diagnostics technology to China and North Asia, in particular Korea and Taiwan.
The company…
